Brought to you by 
Pfizer licenses RTP801 gene, biomolecules from Quark
03 May 2012
Executive Summary
Quark Biotech (therapeutics for diseases of the eye, kidney, and lungs) licensed Pfizer exclusive worldwide rights to develop the RTP801 gene (and molecules that modify its expression or function) as a treatment for wet age-related macular degeneration.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer licenses RTP801 gene, biomolecules from Quark
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice